Bd aims to save lives by empowering women with choice and access to cervical cancer screening self-collected at home

New fda submission includes self-collection swab and high-tech laboratory robotics that report more high-risk hpv strains than any other test franklin lakes, n.j. , july 31, 2025 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced it has submitted an application to the u.s. food and drug administration for a new, at-home human papillomavirus (hpv) test that enables patients to self-collect a sample in the comfort of their own home using a swab the size of a q-tip that simplifies processing at the lab and reports more high-risk strains of hpv than any other test on the market today.
BDX Ratings Summary
BDX Quant Ranking